Meeting
2020 ASCO Virtual Scientific Program
A phase Ib study of nivolumab plus trastuzumab with S-1/capecitabine plus oxaliplatin for HER2-positive advanced gastric cancer (Ni-HIGH study): Safety evaluation.
Authors
Daisuke Takahari
Department of Gastroenterology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
Daisuke Takahari , Hirokazu Shoji , Keiko Minashi , Hiroki Hara , Keisho Chin , Akira Ooki , Mariko Ogura , Izuma Nakayama , Ken Kato , Satoru Iwasa , Hidekazu Hirano , Yusuke Amanuma , Naoki Ishizuka , Narikazu Boku , Kensei Yamaguchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
000034222
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4525)
DOI
10.1200/JCO.2020.38.15_suppl.4525
Abstract #
4525
Poster Bd #
133
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
A phase Ib study of nivolumab plus trastuzumab with S-1/capecitabine plus oxaliplatin for HER2 positive advanced gastric cancer (Ni-HIGH study).
First Author: Daisuke Takahari
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Safety and early efficacy results of a phase Ib study of nivolumab plus trastuzumab with S-1/capecitabine plus oxaliplatin for HER2-positive advanced gastric cancer (Ni-HIGH study).
First Author: Daisuke Takahari
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Atezolizumab and trastuzumab plus chemotherapy in patients with HER2+ locally advanced resectable gastric cancer or adenocarcinoma of the gastroesophageal junction: A multicenter, randomized, open-label phase II study.
First Author: Zhi Peng
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results.
First Author: Yelena Y. Janjigian